Enriched hematopoetic stem cell infusion (University of Louisville)

N/A

Report date: 2023/03/04 20:00:25

Base Information

Drug NameEnriched hematopoetic stem cell infusion (University of Louisville)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsRejection of renal transplantationMucopolysaccharidosis Ialpha-Mannosidosis +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Louisville
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTalaris Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantationMucopolysaccharidosis Ialpha-Mannosidosis +[17] 

Other Information

ATC CodeN/A
Related LinksN/A